The article, “Regulating Private Equity in Health Care: A Strategic Policy Agenda,” published in the May 2026 issue of The American Journal of Managed Care® (AJMC®), presents a strategic policy framework aimed at increasing transparency and safeguarding clinical autonomy as private equity investment expands across the health care sector. The authors present their framework as a means of shielding patients, providers, and practices from the risks of private equity. Becker's ASC Review references this agenda in its analysis of the "trillion-dollar private equity conundrum," covering the ways that private equity could be addressed based on the study from AJMC.
The study “Ambient AI Tool Adoption in US Hospitals and Associated Factors,” published in the January 2026 issue of AJMC, examines the current landscape of ambient AI adoption in US hospitals, identifying that nonprofit health systems and those with higher staffing-adjusted workloads are more likely to be the primary early adopters. The researchers highlight that although the technology promises to reduce documentation burdens, adoption is often driven by institutional resources rather than just clinical need. Becker’s Health IT referenced these findings to contextualize the rapid scaling of ambient AI across the industry, linking the study's data on adoption factors to emerging evidence that these tools can significantly mitigate provider burnout.
The study, "Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns,” published in the August 2025 issue of AJMC, analyzes the rapid expansion of glucagon-like peptide-1 receptor agonist prescriptions, noting a significant shift in patient demographics and the rise of off-label use for weight management. The researchers highlight how the surge in prescribing is increasingly driven by younger patient populations who may not meet traditional clinical criteria for these medications. Medical News Bulletin references these prescribing trends to discuss concerns from health care professionals that the increased availability of lower-cost or compounded versions of drugs like Wegovy could exacerbate risks for individuals with eating disorders.
The article, “FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss,” published on AJMC.com, the website of AJMC, details the FDA’s landmark approval of oral semaglutide as the first GLP-1 receptor agonist available in pill form for chronic weight management, offering a noninvasive alternative to traditional weekly injections. This shift in delivery method is highlighted by Buffalo Business First as a major factor in the broadening accessibility and patient demand for GLP-1 therapies within the workforce. By referencing the FDA approval, the report advises Western New York employers on the fiscal and administrative implications of these expanding drug classes, emphasizing that more convenient oral options will likely drive higher utilization and necessitate revised benefit strategies.
The article, “Congress Grills Hospital CEOs on Rising Health Care Costs,” published on AJMC.com, covers a high-profile congressional hearing where hospital executives faced intense scrutiny over the lack of pricing transparency and the role of vertical integration in driving up medical expenses. The report details how lawmakers questioned the correlation between hospital consolidation and the significant increase in out-of-pocket costs for patients. HealthExec references this coverage to highlight the growing political pressure on health system leaders, specifically focusing on the blunt rhetoric used by representatives who accused hospitals of "charging an insane amount for care."
The article, “PCOS Renamed PMOS in Landmark Shift Reflecting Metabolic and Endocrine Features,” published on AJMC.com, discusses the major medical shift to rename polycystic ovary syndrome (PCOS) to polycystic metabolic-ovarian syndrome (PMOS) to better reflect the condition's complex endocrine and metabolic roots. The change aims to move the clinical focus beyond reproductive symptoms alone, highlighting critical issues like insulin resistance and long-term cardiovascular risks. GMA News Online references this update to explain how the new terminology may help patients receive more holistic care and reduce the confusion caused by a name that previously overemphasized the presence of ovarian cysts.
